Why Appendix Cancer is NOT colon cancer and why that’s important distinction when it comes to treatment

If you or someone you love has appendix cancer, you’ve probably heard this phrase before:

“We treat it like colorectal cancer.”

Tonight’s webinar with Dr. John Paul Shen (MD Anderson) explains why that approach is often wrong and how new research is finally changing the treatment landscape for appendiceal cancer.

This session is packed with information patients and caregivers rarely get in one place. Here’s what Dr. Shen will be walking us through.

Appendix cancer is biologically different from colon cancer

One of the most important messages of the webinar is this:

Appendix cancer is not just a rare version of colon cancer.
It is a biologically distinct disease.

Dr. Shen will explain how appendix cancer differs from colon cancer in:

• Histology (what the tumor looks like under the microscope)
• Genetics and mutations
• How it spreads (most often within the abdomen)
• Tumor microenvironment (the non-cancer cells surrounding the tumor)
• Response to chemotherapy and immunotherapy
• Blood-based monitoring (ctDNA)

These differences are not subtle — they exist at every molecular level.

Why standard colon-cancer chemotherapy often doesn’t work

For many patients, this is the most surprising (and validating) part of the talk.

Dr. Shen will review data showing that 5-FU–based chemotherapy, commonly used for colon cancer:

• Is ineffective in low-grade appendiceal cancer
• Does not slow tumor growth compared to observation
• Has zero objective tumor responses in some studies

He’ll also address the lack of evidence supporting adjuvant chemotherapy (chemo after surgery) in early-stage appendiceal cancer.

This helps explain why so many patients feel like chemo “did nothing” because in many cases, it truly didn’t.

Why expert pathology review is critical

Appendiceal cancer includes multiple subtypes, including:

• Low-grade mucinous tumors (LAMN)
• High-grade tumors (HAMN: signet ring cell or poorly differentiated adenocarcinomas)
• Goblet cell adenocarcinoma, which is its own disease entirely

Dr. Shen will emphasize that:

• Misclassification happens
• Treatment decisions depend heavily on accurate grading and subtype
• Expert pathology review can change management

---

The tumor microenvironment: why treatment response is different

Unlike many cancers, appendiceal tumors often contain:

• Very few actual cancer cells
• Large amounts of mucus
• Many immune and support cells

This “tumor microenvironment” helps explain:

• Why immunotherapy often fails
• Why blood tests can be misleading
• Why therapies targeting the environment — not just tumor cells — may work better

Dr. Shen will discuss how advanced testing can analyze this environment even when tumor tissue is scarce.

New and emerging treatment strategies

This webinar is not just about what doesn’t work. It’s about what is starting to work.

Topics include:

• Bevacizumab (Avastin) improving survival when added to chemotherapy
• CDK4/6 inhibitors (like palbociclib) as a promising option for low-grade mucinous disease
• Immunotherapy combinations for selected patients
• KRAS inhibitors, showing strong activity in certain appendiceal tumors
• Intraperitoneal therapies, including paclitaxel and PIPAC
• Active and upcoming clinical trials at MD Anderson and other centers

Why this matters for patients and caregivers

Appendiceal cancer is an orphan disease. There are:

• No FDA-approved systemic therapies
• Few large clinical trials
• Limited guidelines that truly fit the disease

Progress is coming from:

• Specialized centers
• Real-world patient data
• Research labs deeply focused on appendix cancer biology

Tonight’s webinar is about closing the gap between what patients experience and what the science is now showing.

Who should attend?

This webinar is especially important if you are:

• Newly diagnosed
• Living with appendiceal cancer (patients and caregivers)
• Pre/Post-Surgery, Chemo, HIPEC and monitoring
• Experiencing recurrence
• Feeling uncertain about whether your treatment plan truly fits your disease

We hope you’ll join us tonight for this important conversation. Knowledge matters – especially with a rare cancer.